KPTI — Karyopharm Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1503802 ·
Last close
$0.60
Market Cap
$13.61M
52W High
$10.99
52W Low
$0.60
ADV30
1,455,637
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 33,432,000 | 32,347,000 | -22,526,000 | -67,023,000 | 111,317,000 | 54,980,000 | 441,485,000 |
| Mar 2026 | 35,066,000 | 33,721,000 | -26,760,000 | -22,392,000 | 131,417,000 | 90,850,000 | 397,063,000 |
| Dec 2025 | 34,079,000 | 32,595,000 | -17,844,000 | -102,198,000 | 108,416,000 | 60,540,000 | 401,342,000 |
| Sep 2025 | 44,044,000 | 41,931,000 | -15,220,000 | -33,127,000 | 96,232,000 | 37,672,000 | 365,490,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,113,000
Investing CF
$31,290,000
Financing CF
$79,850,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.09
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,781,891,000
Inventory
$3,599,000
Receivables
$23,357,000
ST Investments
$0
EBIT TTM
$-147,553,000
Pretax Income TTM
$-194,961,000
Interest Exp TTM
$47,408,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$146,620,992
EBITDA
$-82,201,000
Free Cash Flow
$-29,674,250
Enterprise Value
$299,942,144
Total Cash
$65,105,000
Total Debt
$328,529,984
Shares Out
22,681,460
Trailing EPS
$-14.33
Book Value
$-14.56
ROE
—
ROA
-47.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 146,067,000 | -90,707,000 | -196,039,000 | 108,416,000 | 401,342,000 | -292,926,000 | -75,369,000 |
| Dec 2024 | 145,237,000 | -119,443,000 | -76,422,000 | 164,418,000 | 350,435,000 | -186,017,000 | -127,486,000 |
| Dec 2023 | 146,033,000 | -129,540,000 | -143,099,000 | 240,438,000 | 376,644,000 | -136,206,000 | -92,723,000 |
| Dec 2022 | 157,074,000 | -142,202,000 | -165,291,000 | 358,172,000 | 374,828,000 | -16,656,000 | -149,554,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$151,118,000
NetIncome TTM
$-194,969,000
OpCashFlow TTM
—
Assets (Latest)
$131,417,000
Forward EPS
$-2.82
Max Pain — expiry 2028-01-21
max pain strike: $1.00 · spot: $0.57 · call oi: 5 · put oi: 9,420
Expected Move to 2028-01-21:
±$1.02
(178.60%) —
implied range
$-0.45 –
$1.60
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BFRI | Biofrontera Inc. | $13.65M | $0.92 | — |
| SYBX | SYNLOGIC, INC. | $13.47M | $1.10 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $13.42M | $0.49 | — |
| CLRB | Cellectar Biosciences, Inc. | $13.23M | $1.40 | — |
| HIND | Vyome Holdings, Inc | $14.25M | $2.03 | — |
News headlines (Yahoo Finance, 1h cache)
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-11 09:37 · Yahoo
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:05 · Yahoo
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
2026-08-20 13:43 · Yahoo
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
2026-08-13 23:09 · Yahoo
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 12:50 · Yahoo
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
2026-08-13 11:30 · Yahoo
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
2026-08-07 09:37 · Yahoo
Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint
2026-07-31 11:02 · Yahoo
Why Is KPTI Stock Down 69% After-Hours Today?
2026-07-30 22:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.